• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by AstraZeneca PLC

    2/3/26 3:21:18 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email
    S-8 1 tm264269d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 2, 2026

    Registration No. 333-        

     

     

    UNITED STATES SECURITIES AND EXCHANGE
    COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT
    Under
    THE SECURITIES ACT OF 1933

     

     

     

    ASTRAZENECA PLC
    (Exact name of registrant as specified in its charter)

     

    England and Wales
    (State or other jurisdiction of incorporation or
    organization)
    Not Applicable
    (I.R.S. Employer Identification No.)

     

    1 Francis Crick Avenue
    Cambridge Biomedical Campus
    Cambridge CB2 0AA
    England
    (Address of principal executive offices) 

     

     

     

    ASTRAZENECA RESTRICTED SHARE PLAN

    ASTRAZENECA GLOBAL RESTRICTED STOCK PLAN

    ASTRAZENECA EXTENDED INCENTIVE PLAN

    ASTRAZENECA DEFERRED BONUS PLAN

    ASTRAZENECA PERFORMANCE SHARE PLAN 2020

    ASTRAZENECA SAVINGS RELATED SHARE OPTION SCHEME

    ASTRAZENECA SHARE INCENTIVE PLAN

    ASTRAZENECA SHAREPLUS PLAN
    (Full title of the plan)

     

    CT Corporation System
    28 Liberty Street
    New York, NY 10005
    Tel: +1-212-894-8940
    (Name, address and telephone number of agent for service)

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

     

    x Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company
          ¨ Emerging growth company

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) registers (i) 1,086,071 Ordinary Shares, par value $0.25 each (“Ordinary Shares”), of AstraZeneca PLC (the “Company” or the “Registrant”) that may be offered or sold upon exercise of outstanding options previously granted under the AstraZeneca Savings Related Share Option Scheme and (ii) 25,865,874 Ordinary Shares that may be offered or sold, in connection with the AstraZeneca Restricted Share Plan, AstraZeneca Global Restricted Stock Plan, AstraZeneca Extended Incentive Plan, AstraZeneca Deferred Bonus Plan, AstraZeneca Performance Share Plan 2020, AstraZeneca Savings Related Share Option Scheme, AstraZeneca Share Incentive Plan and the AstraZeneca SharePlus Plan (the “Plans”).

     

    PART I

     

    The information specified in Item 1 and Item 2 of Part I of this Registration Statement is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). The documents containing the information specified in Part I will be delivered to the participants in the Plans covered by this Registration Statement as required by Rule 428(b)(1).

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents and information previously filed with the U.S. Securities and Exchange Commission (the “Commission”) by the Company are incorporated herein by reference:

     

    (a)The Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024 (File No. 001-11960), filed with the Commission on February 18, 2025.

     

    (b)The Company’s Current Reports on Form 6-K filed with the Commission on February 18, 2025.

     

    (c)The description of the Company’s Ordinary Shares contained in the Company’s registration statement on Form 8-A (File No. 001-11960), filed with the Commission on January 22, 2026, including any amendment or report filed for the purpose of updating such description.

     

    In addition, all documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and, to the extent, if any, the Company designates therein, reports on Form 6-K the Company furnishes to the Commission on or after the date of this Registration Statement, but prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

     

    Each document incorporated by reference is current only as of the date of such document, and the incorporation by reference of such document shall not create any implication that there has been no change in the affairs of the Company since its date thereof or that the information contained in it is current as of any time subsequent to its date. Any statement contained in this Registration Statement or in a document incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a subsequent statement contained in this Registration Statement or in any subsequently filed document that is deemed to be incorporated by reference in this Registration Statement modifies or supersedes such statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    2

     

     

    Item 5. Interests of Named Experts and Counsel.

     

    Sebastian Kramer, who is issuing the opinion on the legality of the securities offered hereby, is an Assistant General Counsel of the Registrant and holds Ordinary Shares and unvested share awards of the Registrant. Sebastian Kramer is eligible to participate in the AstraZeneca Global Restricted Stock Plan.

     

    Item 6. Indemnification of Directors and Officers.

     

    Deeds of Indemnity

     

    The Company has entered into Deeds of Indemnity with the directors of the Company that provide that, subject to certain conditions precedent and limitations, in consideration for such director or officer continuing in, or accepting, office as a director or officer of (i) the Company or (ii) any of the Company’s subsidiaries, the Company will indemnify and hold the director harmless in respect of all (a) claims, actions and proceedings and (b) losses, damages, penalties, liabilities, compensation or other awards, or any settlement thereof to which the Company consents, arising in connection with any claims, actions or proceedings (whether instigated, imposed, incurred or settled under the laws of any jurisdiction) for negligence, default, breach of duty, breach of trust or otherwise, arising out of, or in connection with, the actual or purported exercise of, or failure to exercise any of the director’s powers, duties or responsibilities as a director or officer of the Company or any of its subsidiaries or which otherwise arises by virtue of the director holding or having held such a position.

     

    Article 97.2 of the Articles of Association of the Company provides:

     

    “Without prejudice to the provisions of Article 140, the board may exercise all the powers of the Company to purchase and maintain insurance for or for the benefit of any person who is or was:

     

    (a) a director, officer, or employee of the Company, or any body which is or was the holding company or subsidiary undertaking of the Company, or in which the Company or such holding company or subsidiary undertaking has or had any interest (whether direct or indirect) or with which the Company or such holding company or subsidiary undertaking is or was in any way allied or associated; or

     

    (b) a trustee of any pension fund in which employees of the Company or any other body referred to in Article 97.2(a) are or have been interested,

     

    including, without limitation, insurance against any liability incurred by such person in respect of any act or omission in the actual or purported execution or discharge of that person’s duties or in the exercise or purported exercise of that person’s powers or otherwise in relation to that person’s duties, powers or offices in relation to the relevant body or fund.”

     

    Article 140 of the Articles of Association of the Company provides:

     

    “Subject to the provisions of the Companies Acts, but without prejudice to any indemnity to which the person concerned may otherwise be entitled, every director or other officer of the Company (other than any person (whether an officer or not) engaged by the Company as auditor) shall be indemnified out of the assets of the Company against any liability incurred by such director or other officer for negligence, default, breach of duty or breach of trust in relation to the affairs of the Company, provided that this Article shall be deemed not to provide for, or entitle any such person to, indemnification to the extent that it would cause this Article, or any element of it, to be treated as void under the Act or otherwise under the Companies Acts.”

     

    3

     

     

    Section 232 of the Companies Act 2006 provides:

     

    (1) Any provision that purports to exempt a director of a company (to any extent) from any liability that would otherwise attach to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void.

     

    (2) Any provision by which a company directly or indirectly provides an indemnity (to any extent) for a director of the company, or of an associated company, against any liability attaching to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he is a director is void, except as permitted by—

     

    (a) section 233 (provision of insurance),

     

    (b) section 234 (qualifying third party indemnity provision), or

     

    (c) section 235 (qualifying pension scheme indemnity provision).

     

    (3) This section applies to any provision, whether contained in a company’s articles or in any contract with the company or otherwise.

     

    (4) Nothing in this section prevents a company’s articles from making such provision as has previously been lawful for dealing with conflicts of interest.”

     

    Section 234 of the Companies Act 2006 provides:

     

    (1) Section 232(2) (voidness of provisions for indemnifying directors) does not apply to qualifying third party indemnity provision.

     

    (2) Third party indemnity provision means provision for indemnity against liability incurred by the director to a person other than the company or an associated company.

     

    Such provision is qualifying third party indemnity provision if the following requirements are met.

     

    (3) The provision must not provide any indemnity against—

     

    (a) any liability of the director to pay—

     

    (i) a fine imposed in criminal proceedings, or

     

    (ii) a sum payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature (however arising); or

     

    (b) any liability incurred by the director—

     

    (i) in defending criminal proceedings in which he is convicted, or

     

    (ii) in defending civil proceedings brought by the company, or an associated company, in which judgment is given against him, or

     

    (iii) in connection with an application for relief (see subsection (6)) in which the court refuses to grant him relief.

     

    (4) The references in subsection (3)(b) to a conviction, judgment or refusal of relief are to the final decision in the proceedings.

     

    4

     

     

    (5) For this purpose—

     

    (a) a conviction, judgment or refusal of relief becomes final—

     

    (i) if not appealed against, at the end of the period for bringing an appeal, or

     

    (ii) if appealed against, at the time when the appeal (or any further appeal) is disposed of; and

     

    (b) an appeal is disposed of—

     

    (i) if it is determined and the period for bringing any further appeal has ended, or

     

    (ii) if it is abandoned or otherwise ceases to have effect.

     

    (6) The reference in subsection (3)(b)(iii) to an application for relief is to an application for relief under—

     

    section 661(3) or (4) (power of court to grant relief in case of acquisition of shares by innocent nominee), or

     

    section 1157 (general power of court to grant relief in case of honest and reasonable conduct).

     

    Section 1157 of the Companies Act 2006 provides:

     

    (1) If in proceedings for negligence, default, breach of duty or breach of trust against—

     

    (a) an officer of a company, or

     

    (b) a person employed by a company as auditor (whether he is or is not an officer of the company),

     

    it appears to the court hearing the case that the officer or person is or may be liable but that he acted honestly and reasonably, and that having regard to all the circumstances of the case (including those connected with his appointment) he ought fairly to be excused, the court may relieve him, either wholly or in part, from his liability on such terms as it thinks fit.

     

    (2) If any such officer or person has reason to apprehend that a claim will or might be made against him in respect of negligence, default, breach of duty or breach of trust—

     

    (a) he may apply to the court for relief, and

     

    (b) the court has the same power to relieve him as it would have had if it had been a court before which proceedings against him for negligence, default, breach of duty or breach of trust had been brought.

     

    (3) Where a case to which subsection (1) applies is being tried by a judge with a jury, the judge, after hearing the evidence, may, if he is satisfied that the defendant (in Scotland, the defender) ought in pursuance of that subsection to be relieved either in whole or in part from the liability sought to be enforced against him, withdraw the case from the jury and forthwith direct judgment to be entered for the defendant (in Scotland, grant decree of absolvitor) on such terms as to costs (in Scotland, expenses) or otherwise as the judge may think proper.”

     

    The Company maintains directors’ and officers’ liability insurance which, subject to policy terms and limitations, provides insurance cover against the personal liabilities which directors and officers may incur by reason of their duties. The authorized representative is also entitled to the benefit of the same directors’ and officers’ liability insurance.

     

    5

     

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit
    No.
      Description
    4.1   Articles of Association (incorporated herein by reference to Exhibit 99.1 to Form 6-K filed by the Company on November 3, 2025).
         
    4.2   AstraZeneca Restricted Share Plan.*
         
    4.3   AstraZeneca Global Restricted Stock Plan.*
         
    4.4   AstraZeneca Extended Incentive Plan.*
         
    4.5   AstraZeneca Deferred Bonus Plan.*
         
    4.6   AstraZeneca Performance Share Plan 2020.*
         
    4.7   AstraZeneca Savings Related Share Option Scheme.*
         
    4.8   AstraZeneca Share Incentive Plan.*
         
    4.9   AstraZeneca SharePlus Plan.*
         
    5.1   Opinion of Sebastian Kramer*
         
    23.1   Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.*
         
    23.2   Consent of Sebastian Kramer (included in Exhibit 5.1).*
         
    24.1   Power of Attorney (see signature page hereto).*
         
    107   Filing Fee Table.*

     

     

    * Filed herewith

     

    6

     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement: (i) to include any prospectus required by Section 10(a)(3) of the Securities Act; (ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and (iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that the undertakings set forth in clauses (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those clauses is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered that remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference into the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    7

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, AstraZeneca PLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in London on February 2, 2026.

     

      ASTRAZENECA PLC
       
      By: /s/ Matthew Bowden
        Name: Matthew Bowden
        Title: Company Secretary

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below hereby constitutes and appoints Matthew Bowden, Hannah Tattersall and Camilla Johnstone (with full power to each of them to act alone), as such person’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign and file with the Securities and Exchange Commission any and all amendments and post-effective amendments to this Registration Statement, with exhibits thereto and any and all other documents that may be required in connection therewith, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and agent, or any substitutes therefor, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Name   Title   Date
             
    /s/ Pascal Soriot   Executive Director and Chief Executive Officer   February 2, 2026
    Pascal Soriot   (Principal Executive Officer)    
             
    /s/ Aradhana Sarin   Executive Director and Chief Financial Officer   February 2, 2026
    Aradhana Sarin   (Principal Financial Officer)    
             
    /s/ Mani Sharma   SVP, Group Controller and Head of Global Finance Services   February 2, 2026
    Mani Sharma   (Principal Accounting Officer)    
             
    /s/ Michel Demaré   Non-Executive Chair of the Board   February 2, 2026
    Michel Demaré        
             
    /s/ Philip Broadley   Senior Independent Non-Executive Director   February 2, 2026
    Philip Broadley        
             
    /s/ Euan Ashley   Non-Executive Director   February 2, 2026
    Euan Ashley        
             
    /s/ Birgit Conix   Non-Executive Director   February 2, 2026
    Birgit Conix        

     

    8

     

     

    /s/ Rene Haas   Non-Executive Director   February 2, 2026
    Rene Haas        
             
    /s/ Karen Knudsen   Non-Executive Director   February 2, 2026
    Karen Knudsen        
             
      Non-Executive Director  
    Diana Layfield        
             
    /s/ Anna Manz   Non-Executive Director   February 2, 2026
    Anna Manz        
             
    /s/ Sheri McCoy   Non-Executive Director   February 2, 2026
    Sheri McCoy        
             
    /s/ Tony Mok   Non-Executive Director   February 2, 2026
    Tony Mok        
             
    /s/ Nazneen Rahman   Non-Executive Director   February 2, 2026
    Nazneen Rahman        
             
    /s/ Marcus Wallenberg   Non-Executive Director   February 2, 2026
    Marcus Wallenberg        

     

    Authorized Representative  
       
    /s/ Mariam Koohdary February 2, 2026
    Mariam Koohdary, as duly authorized representative of AstraZeneca PLC in the United States  

     

    9

     

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Citigroup
    10/27/2025Buy
    Jefferies
    10/16/2025Hold → Sell
    Deutsche Bank
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

    Based on results from TROPION-Breast02, showing AstraZeneca and Daiichi Sankyo's DATROWAY significantly improved overall survival vs. chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if a

    2/3/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

    Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca's DATROWAY significantly improved overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting Daiichi Sankyo (TSE: 4568) and AstraZeneca's (NYSE:AZN) supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug c

    2/3/26 2:30:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca begins trading on the New York Stock Exchange

    Ordinary shares now trade across the NYSE, LSE and STO under a harmonized global listing structure AstraZeneca today begins trading its ordinary shares on the New York Stock Exchange (NYSE) for the first time, enabling more US investors to participate in the Company's strong growth. With this change the trading of AstraZeneca ordinary shares is now aligned across the NYSE, the London Stock Exchange (LSE) and Nasdaq Stockholm (STO) under a harmonized listing structure. Michel Demaré, Chair, AstraZeneca, said: "Today marks the start of an exciting new period for AstraZeneca, one which we believe gives broader access to the largest capital market in the world. This will allow even more inv

    2/2/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on AstraZeneca

    Citigroup initiated coverage of AstraZeneca with a rating of Buy

    1/27/26 8:43:14 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca downgraded by Deutsche Bank

    Deutsche Bank downgraded AstraZeneca from Hold to Sell

    10/16/25 8:19:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    SEC Filings

    View All

    SEC Form S-8 filed by AstraZeneca PLC

    S-8 - ASTRAZENECA PLC (0000901832) (Filer)

    2/3/26 3:21:18 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    2/3/26 7:01:06 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    2/2/26 1:26:35 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Financials

    Live finance-specific insights

    View All

    Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

    Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled hypertension If approved, baxdrostat could be the first aldosterone synthase inhibitor to receive regulatory authorization AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pres

    12/2/25 9:18:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

    Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety profile consistent with the BaxHTN trial Full results presented at the American Heart Association Scientific Sessions 2025 Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the

    11/9/25 4:33:00 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

    Baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in 24-hour ambulatory systolic blood pressure compared with placebo Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.1-3 Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.

    10/7/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    View All

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

    6/6/24 7:00:00 AM ET
    $AZN
    $IMAB
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

    SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

    2/4/22 9:06:48 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

    2/3/21 1:13:21 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care